Yazarlar : Dong M, Phan AT, Yao JC.

Yayın : Clin Cancer Res.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22338018

Konu : Tıbbi Onkoloji

Literatür İçeriği :  

Abstract

Low to intermediate grade neuroendocrine tumor (NET) constitutes a group of indolent malignancies that share the capacity for secreting hormones and neuroamines. Until recently, there were few therapeutic options for oncologic control. The PROMID study demonstrated that octreotide LAR can delay tumor growth in midgut NETs. And, recent phase III studies showed both everolimus and sunitinib improved progression free survival in pancreatic NETs validating the PI3K/Akt/mTOR pathway and angiogenesis as important targets for further advances. Ongoing and planned pivotal studies targeting these pathways in other NET subtypes may widen their therapeutic application. Development of rational combinations may further improve therapeutic outcome. These successes and our improved understanding of the underlying molecular biology are likely to lead to further important advances on the horizon.

Literatür Arşivi